Botanix Pharmaceuticals' (ASX:BOT) shareholders rejected its remuneration report at its annual general meeting on Thursday, according to a same-day Australian bourse filing.
Over 73% of the votes cast at the meeting were against the remuneration report.
The company's shares rose nearly 2% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.